Neuropediatrics, Table of Contents

Neuropediatrics 2022; 53(05): 344-350
DOI: 10.1055/a-1832-9168

Original Article

Is Botox Right for Me: When to Assess the Efficacy of the Botox Injection for Chronic Migraine in Pediatric Population

Ajay Goenka

¹Department of Neurology, Dayton Children Hospital, Wright State University Boonshoft School of Medicine, Dayton, Ohio, United States

²Department of Pediatrics, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, United States

,

Sarah G. Yu

²Department of Pediatrics, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, United States

,

Monica C. George

²Department of Pediatrics, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, United States

,

Mahesh Chikkannaiah

¹Department of Neurology, Dayton Children Hospital, Wright State University Boonshoft School of Medicine, Dayton, Ohio, United States

²Department of Pediatrics, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, United States

,

Sarah MacDonald

¹Department of Neurology, Dayton Children Hospital, Wright State University Boonshoft School of Medicine, Dayton, Ohio, United States

,

Adrienne Stolfi

²Department of Pediatrics, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, United States

,

Gogi Kumar

¹Department of Neurology, Dayton Children Hospital, Wright State University Boonshoft School of Medicine, Dayton, Ohio, United States

²Department of Pediatrics, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, United States

› Author Affiliations

Abstract

Botulinum toxin type A (BoNT-A) has shown to be a safe and effective treatment for children with chronic migraines. Our study was to assess the efficacy of the Onabotulinum toxin type A at different intervals after initiation of therapy. We conducted a retrospective and prospective analysis of 34 patients at a children's hospital where children received four rounds of the BoNT-A therapy for the treatment of chronic migraine. Among the 34 patients, 25 patients (age range: 13–21 years), who responded to the BoNT-A therapy, were included in the analysis. Patients received standard 31 injection, 155 unit's protocol. Patients were assessed every 3 months after their initial injection. Reasons for discontinuation of therapy were analyzed. After the first two BoNT-A sessions, significant improvement was observed with a decrease in headache frequency and intensity (p < 0.001). There was further reduction in headache frequency and intensity with the fourth round of BoNT-A therapy, with comparative analysis between the second and fourth round showing a p-value of <0.001. In terms of reduction of emergency room visits and hospitalization, a significant improvement was seen after the third round of BoNT-A therapy (p < 0.01). A significant decrease in the number of abortive and preventive medications was seen after the second round of BoNT-A therapy (p < 0.001). The efficacy of BoNT-A treatment in decreasing headache frequency, intensity, and the number of abortive and preventive medications can be assessed effectively after two treatment sessions. This trend continued to be observed with additional third and fourth sessions.

Keywords

Keywords

onabotulinum toxin type A - migraine - pediatrics

References
1 Marcelo R, Freund B. The efficacy of botulinum toxin in pediatric chronic migraine: a literature review. J Child Neurol 2020; 35 (12) 844-851
2 Santana L, Liu C. Experience of botulinum toxin A injections for chronic migraine headaches in a pediatric chronic pain clinic. J Pediatr Pharmacol Ther 2021; 26 (02) 151-156
3 Wöber-Bingöl C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep 2013; 17 (06) 341
4 Bigal ME, Arruda MA. Migraine in the pediatric population–evolving concepts. Headache 2010; 50 (07) 1130-1143
5 Youssef PE, Mack KJ. Episodic and chronic migraine in children. Dev Med Child Neurol 2020; 62 (01) 34-41
6 Gozubatik-Celik RG, Ozturk M. Evaluation of quality of life and anxiety disorder in children and adolescents with primary headache. Med Bull Haseki 2021; 59 (02) 167-171
7 Shah S, Calderon MD, Wu W, Grant J, Rinehart J. Onabotulinumtoxin A (BOTOX) for ProphylaCTIC treatment of pediatric migraine: a retrospective longitudinal analysis. J Child Neurol 2018; 33 (09) 580-586
8 Ali SS, Bragin I, Rende E, Mejico L, Werner KE. Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients. Cureus 2019; 11 (03) e4343
9 Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Accessed June 7, 2021 at: https://ichd-3.org/1-migraine/1-1-migraine-without-aura/
10 Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 2014; 34 (11) 853-869
11 Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord 2017; 10 (02) 127-135
12 Begasse de Dhaem O, Gharedaghi MH, Rizzoli P. Modifications to the PREEMPT protocol for onabotulinumtoxinA injections for chronic migraine in clinical practice. Headache 2020; 60 (07) 1365-1375
13 Dodick DW, Turkel CC, DeGryse RE. et al; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50 (06) 921-936
14 Cder FDA. Center for drug evaluation and research approval package for. APPLICATION NUMBER: BLA 2010; 103000: S-5215
15 Injection workbook for chronic migraine: guidance for identifying BOTOX candidates, the injection procedure, and discussing treatment with patients. Accessed May 3, 2022 at: https://www.botoxmedical.com/Common/Assets/APC55BL15%20Injection%20Workbook%20FINAL%20elec.pdf
16 Bendtsen L, Sacco S, Ashina M. et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 2018; 19 (01) 91
17 Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF. A randomized trial to evaluate onabotulinumtoxinA for prevention of headaches in adolescents with chronic migraine. Headache 2020; 60 (03) 564-575
18 Chan VW, McCabe EJ, MacGregor DL. VW C. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosci Nurs 2009; 41 (05) 235-243
19 Kabbouche M, O'Brien H, Hershey AD. OnabotulinumtoxinA in pediatric chronic daily headache. Curr Neurol Neurosci Rep 2012; 12 (02) 114-117
20 Shah S, Calderon MD, Crain N, Pham J, Rinehart J. Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population. Reg Anesth Pain Med 2021; 46 (01) 41-48
21 Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. BOTOX CDH Study Group. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45 (04) 315-324
22 Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgström F. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. J Headache Pain 2020; 21 (01) 99
23 Hollier-Hann G, Curry A, Onishchenko K. et al. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ 2020; 23 (01) 113-123
24 Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P. REPOSE Principal Investigators. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain 2019; 20 (01) 26
25 Aurora SK, Dodick DW, Turkel CC. et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30 (07) 793-803
26 Aurora SK, Winner P, Freeman MC. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51 (09) 1358-1373
27 Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010; 50 (09) 1406-1418
28 Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018; 19 (01) 13